Every claim, graded against its study.

They share a shelf heading, not a mechanism. Here is the four-point test I run before I let the word "versus" into a sentence about two compounds.

They share an address inside the cell and almost nothing else, which is why reading one's evidence into the other will steer you wrong.

The GH-axis peptides are not one evidence base, they're a steep ladder, and the rung most buyers think they're standing on isn't the one they're on.

The prevention result is one of the stronger things in the incretin literature, and the screenshot version of it can't answer any of the three questions that would make it usable.

Five fields decide whether a certificate of analysis describes the vial in your hand or one somebody tested once, two years ago, and you can check all five in thirty seconds.

The claim everyone repeats is factually wrong and directionally right, here's the evidence ladder that settles it in one question.

Two distinct proposed mechanisms, one shared evidence ceiling, and no published study that tested the pair against either compound alone.

Purity tells you the composition of what's in the vial. It says nothing about how much is in there, and almost every certificate published to buyers answers the first question and quietly skips the second.

A new scoping review mapped 80 studies on thymosin beta-4 and TB-500, and exactly one of them studied TB-500 directly. Here's what that does to every claim on the market.